{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T09:08:27Z","timestamp":1697447307094},"reference-count":13,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminoncol.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1053\/j.seminoncol.2016.11.005","type":"journal-article","created":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T14:00:23Z","timestamp":1479132023000},"page":"695-696","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment of high-risk smoldering myeloma"],"prefix":"10.1053","volume":"43","author":[{"given":"Neha","family":"Korde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2016.11.005_bib1","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.005_bib2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2016.11.005_bib3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.005_bib4","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Perez-Persona","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.005_bib5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.005_bib6","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminoncol.2016.11.005_bib7","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2014.75","article-title":"Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma","volume":"28","author":"Merz","year":"2014","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2016.11.005_bib8","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2016.11.005_bib9","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"issue":"Suppl","key":"10.1053\/j.seminoncol.2016.11.005_bib10","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.clml.2014.04.012","article-title":"The road to treating smoldering multiple myeloma","volume":"14","author":"Korde","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.seminoncol.2016.11.005_bib11","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.11.005_bib12","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminoncol.2016.11.005_bib13","first-page":"3","article-title":"Genetic plasma cell signatures in high-risk smoldering myeloma versus multiple myeloma patients","author":"Mailankody","year":"2016","journal-title":"ASCO Annual Meeting"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775416300872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775416300872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T14:54:49Z","timestamp":1536245689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775416300872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0093775416300872"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2016.11.005","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of high-risk smoldering myeloma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2016.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}